Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma. Read more: https://medicalxpress.com/news/2026-08-immune-car-cell-therapy-pediatric.html

Adult childhood cancer survivors treated with anthracyclines have elevated cardiometabolic risk, emphasizing the need for structured cardiac follow-up. Read more: https://www.oncologynurseadvisor.com/news/anthracyclines-cardiometabolic-risk-childhood-cancer-survivors-treatment/

Adult survivors of Hodgkin lymphoma had nearly twice the mortality of the general United States population, according to a population-based retrospective cohort study of 20,057 long-term survivors. Read more: https://www.emjreviews.com/en-us/amj/hematology/news/hodgkin-lymphoma-survivors-face-higher-long-term-mortality/

Survivors of childhood cancer face many of the same emotional challenges as their peers, but they also carry worries that are unique to survivorship. Many know they are at a higher risk of developing chronic conditions earlier in life than other young people, and that awareness can become a lasting source of stress. Read more: https://www.stjude.org/research/progress/2026/emotional-health-supports-physical-health-in-survivors-of-childhood-cancer.html

New insights into why some children with rhabdomyosarcoma (RMS) develop aggressive disease despite being classified as non-high-risk have been uncovered. Read more: https://medicalxpress.com/news/2026-08-hidden-aggressive-cells-reveal-childhood.html

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment outcome in an adolescent with an advanced, treatment-resistant kidney tumor. Read more: https://medicalxpress.com/news/2026-08-personalized-cell-therapy-metastatic-kidney.html

A new, high-quality study reveals that the cardioprotective drug dexrazoxane significantly reduces the heart damage caused by chemotherapy received by pediatric cancer patients 15 years or more after treatment ends. Read more: https://news.ufl.edu/2026/08/chemotherapy-heart-protecting-drug/

Scientists found that the protein promotes survival of KMT2A-rearranged leukemia, presenting a previously unappreciated vulnerability. Read more: https://www.stjude.org/media-resources/news-releases/2026-medicine-science-news/mbnl1-identified-as-potential-cancer-drug-target-for-type-of-childhood-leukemia.html

In a study, Black and Hispanic parents were largely willing to enroll children in oncology trials, while clinicians cited hardship and gatekeeping as barriers. Read more: https://www.cancernetwork.com/view/what-limits-pediatric-oncology-trial-access-for-marginalized-families-

Researchers at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center are zeroing in on less toxic and more targeted strategies to combat Ewing sarcoma, an aggressive and rare pediatric cancer that develops in the bones and soft tissues. Read more: https://medicalxpress.com/news/2026-08-biochemists-strategy-combat-pediatric-bone.html